



Pippias, M., Stel, V., Kramer, A., Abad Diez, J. M., Aresté-Fosalba, N., Ayav, C., Buturovic, J., Caskey, F. J., Collart, F., Couchoud, C., De Meester, J., Heaf, J. G., Helanterä, I., Hemmelder, M. H., Kostopoulou, M., Noordzij, M., Pascual, J., Palsson, R., Reisæter, A. V., ... Jager, K. J. (2018). Access to kidney transplantation in European adults aged 75–84 years and related outcomes: an analysis of the European Renal Association–European Dialysis and Transplant Association Registry. *Transplant International*, 31(5), 540-553. <https://doi.org/10.1111/tri.13125>

Peer reviewed version

License (if available):  
Unspecified

Link to published version (if available):  
[10.1111/tri.13125](https://doi.org/10.1111/tri.13125)

[Link to publication record on the Bristol Research Portal](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at <https://onlinelibrary.wiley.com/doi/abs/10.1111/tri.13125> . Please refer to any applicable terms of use of the publisher.

## University of Bristol – Bristol Research Portal

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/brp-terms/>

# Access to kidney transplantation in European adults aged 75 to 84 years and related outcomes: An analysis of the ERA-EDTA Registry database

**Pippias** Maria MBChB<sup>1</sup>, **Stel** Vianda S. PhD<sup>1</sup>, **Kramer** Anneke PhD<sup>1</sup>, **Abad Diez** Jose M. MD<sup>2</sup>, **Aresté-Fosalba** Nuria MD<sup>3</sup>, **Ayav** Carole MD<sup>4</sup>, **Buturovic** Jadranka MD PhD, Professor<sup>5,6</sup>, **Caskey** Fergus J. MD<sup>7,8</sup>, **Collart** Frederic MD<sup>9</sup>, **Couchoud** Cécile MD, PhD<sup>10</sup>, **De Meester** Johan MD PhD<sup>11</sup>, **Heaf** James G. MD DMSc.<sup>12</sup>, **Helanterä** Ilkka MD PhD<sup>13</sup>, **Hemmelder** Marc H. MD PhD<sup>14</sup>, **Kostopoulou** Myrto MD MSc<sup>15</sup>, **Noordzij** Marlies PhD<sup>1</sup>, **Pascual** Julio MD PhD<sup>16</sup>, **Palsson** Runolfur MD, Professor<sup>17,18</sup>, **Reisæter** Anna Varberg MD, PhD<sup>19</sup>, **Traynor** Jamie P. MD<sup>20</sup>, **Massy** Ziad MD, PhD, Professor<sup>21,22</sup>, **Jager** Kitty J. MD, PhD, Professor<sup>1</sup>

1 ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam Public Health research institute, Amsterdam, the Netherlands

2 Servicio Aragonés de la Salud, Gobierno de Aragón, Spain

3 Department of Nephrology, University Hospital Virgen Macarena, Seville, Spain

4 Inserm, CIC 1433 Clinical Epidemiology, CHRU de Nancy, France

5 Department of Nephrology, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia

6 Faculty of Medicine, University of Ljubljana, Slovenia

7 UK Renal Registry, Southmead Hospital, Bristol, UK BS10 5NB

8 Population Health Sciences, University of Bristol, UK BS8 2PS

9 French-Belgian ESRD Registry, Brussels, Belgium

10 REIN registry, Agence de la biomédecine, Saint-Denis La Plaine, France

11 Department of Nephrology, Dialysis and Hypertension, Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium

12 Department of Medicine, Zealand University Hospital, Roskilde, Denmark

- 13 Helsinki University Hospital, Transplantation and Liver Surgery, Helsinki, Finland
- 14 Dutch Renal Replacement Registry (RENINE), Nefrovisie foundation, Utrecht, the Netherlands
- 15 Department of Nephrology, General Hospital "G. Gennimatas", Athens, Greece
- 16 Department of Nephrology, Hospital del Mar, Barcelona, 08003, Spain
- 17 Division of Nephrology, Landspítali - The National University Hospital of Iceland, Reykjavik, Iceland
- 18 Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- 19 Department of Transplantation Medicine, Oslo University hospital, Rikshospitalet, Norway
- 20 Scottish Renal Registry, Meridian Court, ISD Scotland, Glasgow G2 6QE, United Kingdom
- 21 Division of Nephrology, Ambroise Paré University Hospital, APHP, University of Paris Ouest-Versailles-St-Quentin-en-Yvelines (UVSQ), Boulogne-Billancourt/Paris, France.
- 22 Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Team 5, CESP UVSQ, and University Paris Saclay, Villejuif, France

Correspondence and off-print requests to:

M. Pippias

ERA-EDTA Registry, Department of Medical Informatics,

Academic Medical Center, University of Amsterdam

P.O. Box 22700, 1100 DE Amsterdam, the Netherlands

Telephone +31205661406

E-mail: [m.pippias@amc.uva.nl](mailto:m.pippias@amc.uva.nl)

Running title: Kidney transplantation in European adults aged 75 to 84 years

Key words: Elderly, epidemiology, graft survival, kidney transplantation, Europe

**Authorship:** Maria Pippias: participated in research design, data analysis, and in the writing of the paper, she is the guarantor; Vianda S. Stel: participated in research design and in the writing of the paper; Anneke Kramer: participated in data analysis and in the writing of the paper; Jose M. Abad Diez: supplied data for the study and participated in the writing of the paper; Nuria Aresté-Fosalba: supplied data for the study and participated in the writing of the paper; Carole Ayav: supplied data for the study and participated in the writing of the paper; Jadranka Buturovic: supplied data for the study and participated in the writing of the paper; Fergus J. Caskey: participated in the writing of the paper; Frederic Collart: supplied data for the study and participated in the writing of the paper; Cécile Couchoud: supplied data for the study and participated in the writing of the paper; Johan De Meester: supplied data for the study and participated in the writing of the paper; James G. Heaf: supplied data for the study and participated in the writing of the paper; Ilkka Helanterä: supplied data for the study and participated in the writing of the paper; Marc H. Hemmelder: supplied data for the study and participated in the writing of the paper; Myrto Kostopoulou: supplied data for the study and participated in the writing of the paper; Marlies Noordzij: participated in the writing of the paper; Julio Pascual: supplied data for the study and participated in the writing of the paper; Runolfur Palsson: supplied data for the study and participated in the writing of the paper; Anna Varberg Reisæter: supplied data for the study and participated in the writing of the paper; Jamie P. Traynor: supplied data for the study and participated in the writing of the paper; Ziad Massy: participated in the writing of the paper; Kitty J. Jager: participated in research design and in the writing of the paper.

**Transparency Declarations:** All authors declare not receiving support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

The results presented in this paper have not been published previously in whole or part, except in abstract format.

**Funding:** The ERA-EDTA Registry is funded by the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA). This article was written by Maria Pippias et al., on behalf of the ERA-EDTA Registry which is an official body of the ERA-EDTA.

## **Abstract**

To what extent access to, and allocation of kidney transplants and survival outcomes in patients aged  $\geq 75$  years have changed over time in Europe is unclear. We included patients aged  $\geq 75$ -84 years (termed older adults) receiving renal replacement therapy in thirteen European countries between 2005-2014. Country differences and time trends in access to, and allocation of kidney transplants were examined. Survival outcomes were determined by Cox regression analyses. Between 2005-2014, 1,392 older adult patients received 1,406 transplants. Access to kidney transplantation varied from  $\sim 0\%$  (Slovenia, Greece and Denmark) to  $\sim 4\%$  (Norway and various Spanish regions) of all older adult dialysis patients, and overall increased from 0.3% (2005) to 0.9% (2014). Allocation of kidney transplants to older adults overall increased from 0.8% (2005) to 3.2% (2014). Seven-year unadjusted patient and graft survival probabilities were 49.1% (95% confidence interval, 95%CI: 43.6; 54.4) and 41.7% (95%CI: 36.5; 46.8) respectively, with a temporal trend towards improved survival outcomes. In conclusion, in the European dialysis population aged  $\geq 75$ -84 years access to kidney transplantation is low, and allocation of kidney transplants remains a rare event. Though both are increasing with time and vary considerably between countries. The trend towards improved survival outcomes is encouraging. This information can aid informed decision-making regarding treatment options.

## Introduction

The overall number of patients aged  $\geq 75$  years commencing renal replacement therapy (RRT) for end-stage renal disease (ESRD) in most European countries continues to grow (1). In 2014, patients aged  $\geq 75$  years made up 29% of Europe's incident RRT patients and 21% of the prevalent RRT population (2). The European Renal Association–European Dialysis and Transplantation Association (ERA-EDTA) and the European Union Geriatric Medicine Society recently included kidney transplantation amongst their topics of interest for inclusion in the new European guidelines on managing chronic kidney disease in older patients (3).

Most transplant guidelines do not consider older age *per se* as a contraindication to kidney transplantation (4-6). Nevertheless within Europe, only 2.1% of kidney transplants performed in 2012 were allocated to patients aged  $\geq 75$  years (7). Within the United States (US) in 2014, the same percentage (2.1%) of kidney transplants performed in adults were allocated to those aged  $\geq 75$  to 84 years, having increased 10-fold from 0.18% in 1996 (8). To what extent kidney transplant allocation in patients aged  $\geq 75$  years has changed over time in Europe is unclear.

Reports from the US have shown an improved survival of kidney transplant recipients aged  $\geq 75$  years between the 1990s and 2000s (8, 9). While a few European studies with small sample sizes have examined survival of older kidney transplant recipients (10-13), the prognosis of recipients aged  $\geq 75$  years in a large European cohort is lacking. Given the reported differences in patient characteristics and treatment outcomes between the US and European kidney transplant recipients (14), one cannot predict patient outcomes in the European setting based on US data. Knowledge of transplant outcomes in this age group is necessary for both healthcare professionals and potential recipients in order to make informed decisions regarding treatment options.

Using data from 13 European countries for patients aged  $\geq 75$  to 84 years receiving RRT over the past decade, we investigated trends in (1) access to kidney transplantation, (2) kidney transplant

allocation rates, (3) the type of donor utilised for this age group, and (4) the prognosis of these recipients and their grafts.

## **Methods**

The study population comprised prevalent patients aged  $\geq 75$  to 84 years (henceforth termed 'older adults') receiving RRT for ESRD between 2005 and 2014, from 25 national/regional renal registries supplying individual patient data to the ERA-EDTA Registry. These countries/regions were: Austria, Dutch- and French-speaking Belgium, Denmark, Finland, France, Greece, Iceland, the Netherlands, Norway, Slovenia (2008 to 2013), the Spanish regions of Andalusia, Aragon, Asturias, Basque country, Catalonia, Cantabria, Castile-La Mancha, Castile and Leon, Extremadura, Galicia (from 2007), Madrid (from 2008), and Valencia, Sweden and Scotland. In 2014, all registries had 100% coverage of the general population in their region, accounting for 235 million Europeans (30% of the European population). Details of the methods used for data collection can be found in the ERA-EDTA Registry Annual Report (15). In addition, 20 of the 25 registries with the available data provided details on donor age and deceased donor type (heart beating and non-heart beating donor).

We calculated the following trends:

### *1. Access to kidney transplantation among older adult patients receiving RRT*

We defined access to kidney transplantation as the number of transplants performed in older adult patients per calendar year, divided by the number of prevalent older adult dialysis patients on the 31<sup>st</sup> December of that year.

### *2. Allocation of kidney transplants to older adult patients*

This was defined as the number of kidney transplants performed in older adult patients per calendar year divided by the total number of transplants performed in adults ( $\geq 20$  years) in the year in question.



### *3. Age and type of donor utilised in transplanting older adult patients*

For the above three analyses, we included first and subsequent kidney transplants from a living or deceased donor. Analyses were performed separately by country/region, and for all countries/regions combined. For all countries/regions combined, we examined time trends in kidney transplantation using Joinpoint regression (16). The year was taken as the explanatory variable and the observed rate as the outcome. The annual percentage change (APC) was computed using Poisson regression as provided by the Joinpoint regression program (17).

### *4. Patient and graft survival*

Survival analyses were restricted to kidney transplant recipients who received their first transplant when aged  $\geq 75$  to 84 years, between 2005 and 2013. The survival time started with the date of transplantation and ended with the event of interest, a censored observation which included loss to follow-up, or with the end of the follow-up period (31<sup>st</sup> December 2014). For patient survival, the event of interest was patient death. For graft survival there were two types of analyses; for death-censored graft survival, the event of interest was graft failure and the censored event was patient death with a functioning graft. For graft survival, both death with a functioning graft and graft failure were considered events of interest. The kidney transplant recipients were divided into three cohorts, based on the year of transplantation; cohort 1: 2005-2007, cohort 2: 2008-2010, and cohort 3: 2011-2013.

Death- and graft failure rates per 1000-patient years were calculated by dividing the total number of events (deaths or graft failure respectively) by the total person-time at risk. Total person time at risk was calculated by summation of the individual survival times. The Kaplan-Meier method was used to calculate unadjusted survival probabilities and Cox regression analysis to compare adjusted survival probabilities. For the Cox regression analysis we investigated the effect of the year

of transplantation on the hazard of patient death, graft failure and graft failure censored for death. The transplant year 2009 was considered the reference year. Adjustments were made for country of transplantation, age at transplantation, primary renal disease, sex, dialysis vintage, donor age and donor type (living versus deceased donor). In addition a competing risk analysis was performed whereby patient death was considered the event of interest and graft failure resulting in a return to dialysis or re-transplantation and loss to follow-up were considered competing events. All analyses were performed using SAS software 9.4, R version 3.3.1 and Joinpoint 4.0.4 (17). A p-value of less than 0.05 was considered statistically significant.

## **Results**

Between 2005 and 2014, 1,392 older adult patients received 1,406 kidney transplants (Supplementary Table 1). Ninety-six percent (N=1,331) received a first kidney transplant, 4.1% (N=58) a second, and 0.2% (N=3) a third. Fourteen patients received two transplants during the 10-year timeframe whilst aged  $\geq 75$  to 84 years. In 2014, the median age at transplantation was 77.0 years (interquartile range [IQR]: 75.9-78.1). Only 8.9% (N= 125) of the older adults were aged  $\geq 80$  to 84 years at the time of transplantation. In 2014, 71% of all transplant recipients were male, whereas 60% of the prevalent older adult dialysis population were male. There was no statistically significant change in the sex distribution of either group over time.

Of the 1,331 first kidney transplant recipients, 8.3% (N=111) received a pre-emptive transplant, with the majority (77.5%, N=86) occurring during the years 2011 to 2014. Only 15% (N=17) of pre-emptive transplants were from living donors. For the non-pre-emptive transplant recipients, the median dialysis time prior to the first transplant was 2.0 years (IQR: 1.20-3.40).

*Access to kidney transplantation among older adult patients receiving RRT*

The percentage of older adult patients on RRT for ESRD who received a kidney transplant, by country/region and overall, and by year 2005-2014, is shown in Table 1. Access to kidney transplantation was consistently highest in Norway (approximately 4% per year), and the Spanish regions of Aragon, Asturias, Castile-La Mancha, and Madrid, whilst in Slovenia, Greece and Denmark this was 0% or nearly 0%. For all countries/regions combined, access to kidney transplantation in older adult patients rose from 0.30% to 0.90% between 2005 and 2014 (APC: 13.9%, 95% confidence interval [95%CI]: 11.5; 16.3).

#### *Allocation of kidney transplants to older adult patients*

Between 2005 and 2014, 1.8% of the 76,202 transplants performed in patients aged  $\geq 20$  to 84 years in these combined countries/regions were allocated to patients aged  $\geq 75$  to 84 years. Over the 10-year period, the proportion of kidneys allocated to older patients quadrupled from 0.8% in 2005 to 3.2% in 2014 (APC 16.3%, 95%CI: 13.4; 19.2; Table 2 and Supplementary Tables 1 and 2), with a substantial variation seen across Europe. In the later years, 2-5% of all adult kidney transplantations in France, Norway, the Netherlands and Spain (when analysing all regions together and covering 87.5% of the Spanish population) were allocated to older adult RRT patients. Conversely, in Denmark, Greece, and Slovenia this was 0% or nearly 0% (Table 2). Overall the percentage of prevalent older adults (aged  $\geq 75$  to 84 years) receiving dialysis as a proportion of all adult dialysis patients (aged  $\geq 20$  to 84 years) increased from 26.3% in 2005 to 31.1% in 2014 (APC 1.8%, 95%CI: 1.4; 2.2; Supplementary Table 3). Again this varied across the countries/regions, from 21.8% in Scotland (2014) to 41.8% in Dutch-speaking Belgium (2014). Norway was the only country where the percentage of prevalent older adults receiving dialysis as a proportion of all adult dialysis patients significantly declined over the 10-year time period.

#### *Age and type of kidney donor utilised in transplanting older adult patients*

Ninety-one percent (N=1,286) of kidney transplants performed in older adult patients originated from deceased donors, 5.1% (N=71) from living donors, and 3.5% (N=49) from unknown donor sources. For the majority of countries, all kidney allografts in this age group came from deceased donors (Figure 1, left panel). Some countries transplanted kidneys from living donors; however compared with the percentage of living donor kidney transplants performed in recipients aged  $\geq 20$  to 74 years in the same time period, even these countries had a comparatively low number of living donor transplants in older adult patients (Figure 1, right panel). Over the 10-year period, the proportion of deceased donor transplants increased (APC 2.8%, 95%CI: 0.7; 5.0), whilst the percentage of living donor transplants appeared to decline (APC -5.8%, 95%CI: -14.7; 4.1). The median age of deceased donors rose by 10 years, from 67 years (IQR: 57; 73) in 2005 to 77 years (IQR: 70; 80) in 2014 (Figure 2). There were too few living donors to examine annual trends. However, overall the median age of the living donors was lower than that of the deceased donors (60 years, IQR: 52; 71). The median age of deceased donors appeared to be higher in countries/regions with higher transplantation rates in the older adult age group (Supplementary Table 4).

#### *Patient and graft survival*

Between 2005 and 2013, 1,080 older adult patients received their first kidney transplant (Table 3). There were no significant differences in the characteristics of the three transplant cohorts. With each passing transplant cohort the mortality rate per 1000-patient years declined, whereas the number of graft-failure events per 1000-patient years varied from 140.2 (95%CI: 115.1; 165.3) to 115.2 (95%CI: 96.5; 134.0), to 135.5 (95%CI: 113.6; 157.5) over the three time cohorts (Table 4). Seven-year patient survival probability was 48.0% (95%CI: 42.7; 53.0), graft survival probability was 41.3% (95%CI: 36.4; 46.2) and death-censored graft survival probability was 79.2% (95%CI: 75.0; 82.7; Figures 3a, 3b and 3c respectively). There was a trend towards improved adjusted patient and

graft survival with each passing year (Figure 4). The competing risk analysis for the outcome death-censored graft failure is presented in Supplementary figure 1. The most common cause of death was infection (31.7%), followed by a cardiac cause (ischaemic heart disease, heart failure or cardiac arrest) or a cerebrovascular event (21.7%) and death from malignancy (11.3%). The cause of death was unknown for 15.8% of the kidney transplant recipients.

## **Discussion**

Using data from 13 European countries, we found a limited access to and allocation of kidney transplantation among older adult patients. Although the access to kidney transplantation and allocation of kidneys to older adult patients increased over time, both varied considerably between European countries. As the RRT population continues to age, the number of potential older adults eligible for kidney transplantation is likely to increase. Hence the identification of time trends and international variation in access to kidney transplantation is an essential first step in finding explanations for the differences between countries. This is the largest European study on the prognosis of patients receiving a kidney transplant whilst aged  $\geq 75$  to 84 years. We found a trend towards improved patient and graft survival after the first year of transplantation. This information is important for both healthcare professionals and older adult patients with ESRD when considering kidney transplantation as a treatment modality.

### *Access to and allocation of kidney transplants to older adult patients is increasing but varies across countries*

Within the European countries combined, access to kidney transplantation increased somewhat, from 0.3% of all prevalent older adults receiving RRT in 2005 to 0.9% in 2014. In comparison, this figure was 0.3% in 2005 and only 0.4% in 2014 in the US (8). Allocation of kidney transplants to this age group, although relatively rare, has increased over time, from 0.8% of all kidney transplants

performed in adults ( $\geq 20$  years) in 2005 to 3.2% in 2014. In the US, the increase in the allocation of all kidney transplants performed in adults ( $\geq 18$  years) increased modestly from 1.4% to 2.0% over the 10-year period (8).

A striking finding of this study is the substantial variation in the access to and allocation of kidneys to older adult patients across Europe. For example in Norway, where the access to transplantation was highest, 3-4% of prevalent older adult dialysis patients received a kidney transplant each year, whereas in the neighbouring Scandinavian countries this was only 0-1% per year. Possible explanations for this variation include differences between countries in attitudes towards dialysis and kidney transplantation in the older adult, both among healthcare professionals and patients, country-specific healthcare expenditures, organ allocation policies, and the number of available kidneys from older donors. The Eurotransplant Senior Program is a strategy aimed at increasing kidney transplantation rates in older adults (18). Organs from deceased donors aged  $>65$  years are allocated without human leukocyte antigen (HLA) matching to potential recipients aged  $>65$  years, thereby simultaneously increasing the donor pool for older and younger patients. Though active since 1999 in four countries included in this study (Austria, Dutch- and French-speaking Belgium, Slovenia [since 2000] and the Netherlands), the percentage of older adults receiving a deceased donor kidney transplant varied between these countries. Therefore, the difference cannot, in this case, be explained exclusively by a relative shortage of kidneys from older deceased donors or differences in national allocation policies. It is well known that even within countries such as Spain, which has one of the highest organ transplantation rates overall, regional differences do exist (19). In this study we noted a substantial difference in access to and the allocation of kidney transplants in older adults among the regions of Spain, suggesting that access to transplantation in older adult patients may also vary within a country despite having the same allocation policy.

The differences may also lie with the attitudes towards transplantation in general, and transplanting older adults in particular. For example, whilst Greece has one of the highest incidences

of RRT in Europe for both young and older patients, the deceased donor kidney transplantation rates are amongst the lowest in Europe for both young and old individuals (7). Limited education amongst healthcare professionals about organ donation and poor media interest have been suggested as possible causes for the low uptake of organ donation (20, 21). In the United Kingdom, the Netherlands and the US, a systematic review reported that nephrologists recommending transplantation to patients aged >60 years varied from 10 to 59% (22).

It should be noted that access to kidney transplantation in this study reflects the proportion of older adults from the older adult dialysis population receiving a transplant. However, the incidence and the prevalence of older adults receiving dialysis varies between countries (7). The greater the percentage of patients receiving a kidney transplant may therefore reflect a lower incidence of RRT within a country or a lower percentage of prevalent older adults as a proportion of the adult dialysis population. Furthermore given our definition of access to kidney transplantation we do not account for the proportion of older adult patients listed on the kidney transplant waiting list (as this data was unavailable to us). It is likely that this also varies substantially between countries and will play a role in the subsequent allocation of kidney transplants to this age group.

*The majority of allografts utilised in this age group are from old deceased donors*

The vast majority of kidney allografts were from deceased donors, even in countries with traditionally high living donor rates such as the Netherlands and Norway. This could reflect a patient's and/or clinician's apprehension of placing undue risk on either a younger (i.e. offspring) or older (i.e. spouse/partner) donor to surgery for the benefit of an older adult patient. Only 5% of all renal allografts transplanted in this age group were from living donors (8.5% at best, assuming all unknown donor types were living donors). This is in stark contrast to the US where 20% of renal allografts transplanted in this age group were from living donors (8). The difference in the practice of utilising living kidney donors between Europe and the US is well known (23). Though still relatively

small, the number of living donor kidney transplants in patients >65 years in the US has been slowly increasing (24). In our study, the number of kidney grafts from living donors transplanted into older adult patients appeared to decrease. The outcomes of older, i.e.  $\geq 70$  years, living donor renal allografts in older recipients have been shown to be equivalent to those from standard criteria donors (SCD) aged 50 to 59 years (25). Therefore clinically, the greater utilisation of older living donors may prove a useful for increasing the access to transplantation in this age group.

*Deceased kidney donors utilised in this age group are getting older*

During the study period, the median age of the deceased kidney donors rose from 67 to 77 years. This may well reflect the increased acceptance of utilising extended criteria donor (ECD) kidneys, which by definition includes all donors aged >60 years. Patients aged  $\geq 65$  years who accept an ECD kidney within two years of commencing dialysis have a slightly longer life expectancy compared with their counterparts waiting for a SCD or a living donor kidney (26). For patients aged >70 years, there is no relative survival benefit from medium- compared with low-quality kidneys (27). Furthermore, in recipients >70 years ECD kidneys are not significant predictor of death or graft loss (28). In clinical practice, reducing the time spent on dialysis with a kidney transplant from either an older living donor or an ECD may reduce mortality in this age group. Though the median time on dialysis prior to the first kidney transplantation in this study did not change, 77% of the pre-emptive transplants occurred in the last four years, which in the future may translate to improved survival.

*Survival of older kidney transplant recipients may well be improving, though death-censored graft survival remains unchanged*

The trend toward improved post-transplant patient and graft survival over the past decade observed in this study is consistent with outcomes seen in older transplant recipients in the US (9) and in younger recipients in Europe (1). Although this remains, to our knowledge, the largest analysis of



transplant outcomes in older adult European recipients, the relatively small sample size may explain the statistically non-significant trends. Of the older patients who received a kidney transplant during 2005-2013, the 2-year patient survival was 84%. This finding is in line with studies from the US where the reported 2-year probability of patient survival in recipients aged  $\geq 70$  to 79 years and transplanted in 2000-2008 was 85%, whereas the 2-year patient survival in those  $\geq 80$  years was lower at 74% (29). In comparison to graft failure rates, death-censored graft survival rates were very high, indicating that these patients are dying with a functioning graft as a result of their age and/or co-morbidities or transplant-related complications.

The main strength of this study is the inclusion of 13 European countries, with coverage of 235 million individuals, over a 10-year time period in the analysis of kidney transplantation rates, donor sources, and survival outcomes of kidney transplantation, which is a rare event in the older RRT population. By contrast, the study is limited by the lack of information regarding comorbidities and, most importantly, transplant waiting-list status, donor-related factors, such as cause of death, and transplant-related factors, including HLA-match, immunosuppression regimes and acute rejection episodes which have been shown to influence survival outcomes (30). As patient selection patterns and immunosuppression regimes are likely to vary between transplant centres, the survival outcomes will vary at the transplant centre level, therefore these results cannot be considered generalizable to all older adult patients. In this study, we defined access to kidney transplantation as the number of patients receiving a transplant as opposed to the number of wait-listed patients, with the former dependent on the number of available donors. As the number of available donors in countries will vary, our definition is not the ideal approach for country comparisons. However, without access to kidney transplant waiting-list data, we can only provide this type of comparison. It should be noted however that being defined as having access to the waiting-list is not what patients would consider most important; it is actually receiving a kidney transplant. Furthermore, without

access to waiting-list data we were unable to compare survival outcomes between older adult transplant recipients and those receiving dialysis whilst listed on the kidney transplant waiting-list. Knowledge of survival outcomes of patients receiving these different RRT modalities aid informed decision-making regarding treatment options.

## Conclusion

Over the past 10 years, the frequency with which the European RRT population aged  $\geq 75$  to 84 years had access to and were allocated allografts increased. Despite this, kidney transplantation in this older adult age group remains a rare event whose occurrence varies considerably across Europe due to known and unknown reasons. The trend towards improved patient and graft survival is encouraging. Changes in clinical practice policies such as reducing pre-transplant dialysis time by performing an early transplantation using an older living donor kidney or eliminating pre-transplant dialysis altogether by carrying out a pre-emptive transplant, may over time further improve patient survival. However it should be kept in mind that the older adult RRT population in this study are a very select group of individuals. It is vital that older patients are only transplanted when they are likely to benefit from the procedure and, therefore, prediction models identifying which older RRT patients will benefit from kidney transplantation are warranted.

## Acknowledgements

The ERA-EDTA Registry would like to thank the patients and staff of all the dialysis and transplant units who have contributed data via their national and regional renal registries. In addition, we would like to thank the persons and organizations listed in the paragraph “affiliated registries” for their contribution to the work of the ERA-EDTA Registry.

## Affiliated Registries

Austrian Dialysis and Transplant Registry [OEDTR] (R. Kramar); Dutch-speaking Belgian Society of Nephrology [NBVN] (B. De Moor, and F. Schroven); French-speaking Belgian Society of Nephrology [GNFB] (JM. des Grottes); Danish Nephrology Registry [DNS]; Finnish Registry for Kidney Diseases (P. Finne and C. Grönhagen-Riska); France: The Epidemiology and Information Network in Nephrology [REIN] (M. Lassalle); Hellenic Renal Registry (N. Afentakis); Icelandic End-Stage Renal Disease Registry; Norwegian Renal Registry (T. Leivestad, and A. Åsberg); the Netherlands: Dutch Renal Registry (RENINE) (A. Hemke); Spanish Regional Registries of Andalusia [SICATA] (P. Castro de la Nuez), Aragon (J.I. Sanchez Miret), Asturias (R. Alonso de la Torre, J.R. Quirós, and RERCA Working Group), Basque country [UNIPAR] (Á. Magaz, J. Aranzabal, M. Rodrigo, and I. Moina), Cantabria (M. Arias Rodríguez and O. García Ruiz), Castile and León (R. González and C. Fernández-Renedo), Castile-La Mancha (G. Gutiérrez Ávila and I. Moreno Alía), Catalonia [RMRC] (E. Arcos, J. Comas, and J. Tort), Extremadura (J.M. Ramos Aceitero and M.A. García Bazaga), Galicia (E. Bouzas-Caamaño and J. Sánchez-Ibáñez), Community of Madrid (M.I. Aparicio de Madre), and the Valencian region [REMRENAL] (C. Alberich Martí and M. Ferrer Alamar); Swedish Renal Registry [SNR] (K.G. Prütz, M. Stendahl, M. Evans, S. Schön, L. Bäckman, and M. Segelmark); Scottish Renal Registry [SRR] (All of the Scottish renal units); and the other ERA-EDTA Registry Committee members not mentioned above for their advice in the analysis and the drafting of this paper: A. Więcek, M. Evans, J.W. Groothoff, J. Harambat, F. Jarraya, M. Nordio, and I. Rychlik.

In addition we would like to thank the following registries for supplying donor details: Dutch Transplant Foundation (NTS: C. Konijn), Finnish Transplantation Registry (M. Lempinen), Spanish RRT National Registry at ONT (E. Martín Escobar)

## References

1. Pippias M, Jager KJ, Kramer A, Leivestad T, Sanchez MB, Caskey FJ, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. *Nephrol Dial Transplant*. 2016;31(5):831-41.
2. Pippias M, Kramer A, Noordzij M, Afentakis N, Alonso de la Torre R, Ambuhl PM, et al. The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2014: A summary. *Clin Kidney J*. 2017;10(2):154-69.
3. van der Veer SN, van Biesen W, Bernaert P, Bolignano D, Brown EA, Covic A, et al. Priority topics for European multidisciplinary guidelines on the management of chronic kidney disease in older adults. *Int Urol Nephrol*. 2016;48(6):859-69.
4. Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. *CMAJ*. 2005;173(10):1181-4.
5. Dudley C. HP. Clinical Practice Guidelines. Module 4: Assessment for renal transplantation. UK Renal Association. 4th Edition, 2008. 2008.
6. Segall L, Nistor I, Pascual J, Mucsi I, Guirado L, Higgins R, et al. Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease: A Literature Review and Position Statement on Behalf of the European Renal Association-European Dialysis and Transplant Association Descartes Working Group and European Renal Best Practice. *Transplantation*. 2016;100(10):e55-65.
7. Pippias M, Stel VS, Abad Diez JM, Afentakis N, Herrero-Calvo JA, Arias M, et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. *Clin Kidney J*. 2015;8(3):248-61.
8. United\_States\_Renal\_Data\_System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States.: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2016.
9. McAdams-DeMarco MA, James N, Salter ML, Walston J, Segev DL. Trends in kidney transplant outcomes in older adults. *J Am Geriatr Soc*. 2014;62(12):2235-42.
10. Heldal K, Hartmann A, Grootendorst DC, de Jager DJ, Leivestad T, Foss A, et al. Benefit of kidney transplantation beyond 70 years of age. *Nephrol Dial Transplant*. 2010;25(5):1680-7.
11. Perez-Saez MJ, Arcos E, Comas J, Crespo M, Lloveras J, Pascual J, et al. Survival Benefit From Kidney Transplantation Using Kidneys From Deceased Donors Aged  $\geq 75$  Years: A Time-Dependent Analysis. *Am J Transplant*. 2016;16(9):2724-33.
12. Boesmueller C, Biebl M, Scheidl S, Oellinger R, Margreiter C, Pratschke J, et al. Long-term outcome in kidney transplant recipients over 70 years in the Eurotransplant Senior Kidney Transplant Program: a single center experience. *Transplantation*. 2011;92(2):210-6.
13. Heldal K, Leivestad T, Hartmann A, Svendsen MV, Lien BH, Midtvedt K. Kidney transplantation in the elderly--the Norwegian experience. *Nephrol Dial Transplant*. 2008;23(3):1026-31.
14. Ojo AO, Morales JM, Gonzalez-Molina M, Steffick DE, Luan FL, Merion RM, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. *Nephrol Dial Transplant*. 2013;28(1):213-20.
15. ERA-EDTA\_Registry. ERA-EDTA Registry Annual Report 2014. Academic Medical Center, Department of medical informatics, Amsterdam, the Netherlands. 2016.
16. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med*. 2000;19(3):335-51.
17. Joinpoint Regression Program, Version 4.3.1.0 - April 2016; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.

18. de Fijter JW. An old virtue to improve senior programs. *Transpl Int*. 2009;22(3):259-68.
19. Matesanz R, Marazuela R, Dominguez-Gil B, Coll E, Mahillo B, de la Rosa G. The 40 donors per million population plan: an action plan for improvement of organ donation and transplantation in Spain. *Transplantation proceedings*. 2009;41(8):3453-6.
20. Symvoulakis EK, Tsimtsiou Z, Papaharitou S, Palitzika D, Markaki A, Stavroulaki E, et al. Kidney organ donation knowledge and attitudes among health care professionals: findings from a Greek general hospital. *Appl Nurs Res*. 2012;25(4):283-90.
21. Dardavessis T, Xenophontos P, Haidich AB, Kiritsi M, Vayionas MA. Knowledge, attitudes and proposals of medical students concerning transplantations in Greece. *Int J Prev Med*. 2011;2(3):164-9.
22. Tong A, Hanson CS, Chapman JR, Halleck F, Budde K, Papachristou C, et al. The preferences and perspectives of nephrologists on patients' access to kidney transplantation: a systematic review. *Transplantation*. 2014;98(7):682-91.
23. Scoble JE, Burnapp L. Living donor transplantation in the USA: are there any lessons for Europe? *Nephrol Dial Transplant*. 2005;20(6):1034-7.
24. Rowe TA, Huded J, McElroy L, Ladner DP, Lindquist LA. The Evolution of Living Kidney Donation and Transplantation in Older Adults. *J Am Geriatr Soc*. 2015;63(12):2616-20.
25. Berger JC, Muzaale AD, James N, Hoque M, Wang JM, Montgomery RA, et al. Living kidney donors ages 70 and older: recipient and donor outcomes. *Clin J Am Soc Nephrol*. 2011;6(12):2887-93.
26. Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? *Clin J Am Soc Nephrol*. 2006;1(3):532-8.
27. Hernandez RA, Malek SK, Milford EL, Finlayson SR, Tullius SG. The combined risk of donor quality and recipient age: higher-quality kidneys may not always improve patient and graft survival. *Transplantation*. 2014;98(10):1069-76.
28. Molnar MZ, Streja E, Kovesdy CP, Shah A, Huang E, Bunnapradist S, et al. Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2012;59(6):841-8.
29. Huang E, Poommipanit N, Sampaio MS, Kuo HT, Reddy P, Gritsch HA, et al. Intermediate-term outcomes associated with kidney transplantation in recipients 80 years and older: an analysis of the OPTN/UNOS database. *Transplantation*. 2010;90(9):974-9.
30. Haldal K, Hartmann A, Leivestad T, Svendsen MV, Foss A, Lien B, et al. Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity. *Transplantation*. 2009;87(7):1045-51.

Table 1 Percentage of prevalent dialysis patients aged  $\geq 75$  to 84 years on renal replacement therapy for end-stage renal disease who received a kidney transplant, by country/region and overall, and by year during 2005-2014. Where cells are empty data are unavailable.

Country \ Year	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
<b>Austria</b>	0.48	0.59	0.47	0.46	0.32	0.83	0.50	0.90	0.30	0.59
<b>Belgium: Dutch-speaking</b>	0.08	0.15	0.22	0.07	0.13	0.13	0.24	0.18	0.12	0.12
<b>Belgium: French-speaking</b>	0.00	0.00	0.00	0.11	0.22	0.32	0.21	0.31	0.39	0.29
<b>Denmark</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00
<b>Finland</b>	0.00	0.56	0.00	0.28	0.85	0.27	0.81	0.26	0.78	1.02
<b>France</b>	0.23	0.27	0.26	0.26	0.41	0.42	0.40	0.61	0.71	0.92
<b>Greece</b>	0.00	0.00	0.04	0.00	0.04	0.00	0.04	0.00	0.03	0.00
<b>Iceland</b>	0.00	0.00	0.00	0.00	0.00	5.00	0.00	0.00	0.00	0.00
<b>Netherlands</b>	0.75	0.15	0.50	0.26	0.75	0.72	0.75	1.12	1.10	1.02
<b>Norway</b>	2.70	3.34	1.89	2.77	2.88	2.07	4.99	4.06	2.97	3.76
<b>Slovenia</b>			0.00	0.00	0.00	0.00	0.00	0.00	0.00	
<b>Spain: Andalusia</b>	0.73	0.32	0.10	0.09	0.17	0.17	0.41	0.48	0.40	0.48
<b>Spain: Aragon</b>	0.56	1.14	1.60	0.50	2.05	1.86	2.46	2.35	2.67	2.73
<b>Spain: Asturias</b>	0.74	3.97	1.29	0.64	3.36	0.65	0.00	0.56	0.55	2.42
<b>Spain: Basque</b>	0.00	0.00	0.41	0.41	1.85	0.76	1.05	1.37	0.96	0.98
<b>Spain: Catalonia</b>	0.52	0.51	0.34	0.65	0.85	0.89	1.52	1.51	1.72	2.66
<b>Spain: Cantabria</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>Spain: Castile-La Mancha</b>	0.76	2.12	2.11	1.31	0.65	0.97	2.63	1.66	2.19	0.72
<b>Spain: Castile and Leon</b>	0.54	0.26	0.46	0.00	0.44	0.88	1.27	1.07	2.56	2.55
<b>Spain: Extremadura</b>	0.00	0.00	0.00	1.43	0.63	0.59	0.00	0.00	0.00	0.52
<b>Spain: Galicia</b>			0.24	0.22	0.00	0.00	0.56	0.19	0.00	0.00
<b>Spain: Madrid</b>				3.07	2.79	2.96	1.92	2.10	2.59	3.70
<b>Spain: Valencia</b>	0.00	0.00	0.11	0.11	0.20	0.10	0.00	0.37	0.09	0.09
<b>Sweden</b>	0.00	0.00	0.21	0.31	0.00	0.31	0.00	0.92	0.20	0.80
<b>UK: Scotland</b>	0.26	0.00	0.26	0.48	0.24	0.44	0.90	0.23	0.45	0.69
<b>All</b>	0.30	0.31	0.29	0.36	0.49	0.49	0.56	0.67	0.70	0.90

Table 2 Percentage of transplants carried out in adults ( $\geq 20$  years) which were performed in recipients aged  $\geq 75$  to 84 years, by country/region and overall, and by year during 2005-2014.

Where cells are empty, data are unavailable.

<b>Country</b>	<b>Year</b>	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>
<b>Austria</b>		1.1	1.3	0.9	1.3	0.8	2.2	1.1	2.1	0.8	1.6
<b>Belgium: Dutch-speaking</b>		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Belgium: French-speaking</b>		0.0	0.0	0.0	0.6	1.1	1.7	1.0	1.6	2.2	1.8
<b>Denmark</b>		0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0
<b>Finland</b>		0.0	1.0	0.0	0.7	1.8	0.6	1.8	0.5	1.7	1.8
<b>France</b>		0.6	0.8	0.8	0.9	1.6	1.8	1.7	2.6	3.1	3.9
<b>Greece</b>		0.0	0.0	0.4	0.0	0.6	0.0	0.5	0.0	0.6	0.0
<b>Iceland</b>		0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0
<b>Netherlands</b>		1.3	0.3	0.9	0.6	1.6	1.5	1.7	2.3	2.3	2.1
<b>Norway</b>		3.7	4.8	2.3	3.3	3.5	2.8	5.7	4.8	3.8	4.9
<b>Slovenia</b>					0.0	0.0	0.0	0.0	0.0	0.0	
<b>Spain: Andalusia</b>		1.9	0.8	0.3	0.3	0.5	0.6	1.2	1.3	1.2	1.3
<b>Spain: Aragon</b>		1.4	3.1	3.8	1.7	5.6	5.9	6.3	7.0	6.7	7.2
<b>Spain: Asturias</b>		2.1	9.2	3.6	2.5	10.9	2.3	0.0	2.0	1.9	7.8
<b>Spain: Basque</b>		0.0	0.0	0.9	0.9	4.8	1.7	2.7	3.4	1.9	2.4
<b>Spain: Catalonia</b>		1.3	1.5	0.9	1.7	2.2	2.7	3.7	3.8	4.9	6.5
<b>Spain: Cantabria</b>		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Spain: Castile-La Mancha</b>		2.4	7.0	6.9	4.0	2.4	3.7	9.8	5.2	5.6	2.1
<b>Spain: Castile and Leon</b>		1.7	0.9	2.0	0.0	2.2	3.8	5.9	3.9	9.0	8.7
<b>Spain: Extremadura</b>		0.0	0.0	0.0	5.0	2.2	2.4	0.0	0.0	0.0	1.8
<b>Spain: Galicia</b>				1.0	0.8	0.0	0.0	2.1	0.7	0.0	0.0
<b>Spain: Madrid</b>					6.9	6.3	6.6	4.6	4.6	5.9	8.1
<b>Spain: Valencia</b>		0.0	0.0	0.5	0.5	1.0	0.5	0.0	1.8	0.4	0.5
<b>Sweden</b>		0.0	0.0	0.5	0.8	0.0	0.9	0.0	2.4	0.5	1.9
<b>UK: Scotland</b>		0.7	0.0	0.5	1.0	0.5	1.1	2.0	0.4	0.8	1.2
<b>All</b>		0.8	1.0	0.9	1.2	1.7	1.9	2.0	2.5	2.5	3.2

Table 3 Baseline characteristics of patients aged  $\geq 75$  to 84 years who received their first kidney transplant during 2005-2013, and the donor features, by transplant cohort.

<b>Cohort</b>	<b>2005-2007</b>	<b>2008-2010</b>	<b>2011-2013</b>	<b>p-value</b>
<b>Characteristic</b>				
<b>Number of recipients</b>	205	333	542	
<b>Male, % / N</b>	68.8 / 141	66.1 / 219	68.3 / 368	0.74
<b>Age at RRT onset, median (IQR)</b>	74.7 (73.4, 76.2)	74.7 (73.1, 76.4)	75.0 (73.4, 76.6)	0.29
<b>Age at transplantation, median (IQR)</b>	76.3 (75.6, 78.0)	76.8 (75.8, 78.0)	76.9 (75.8, 78.3)	0.70
<b>Dialysis time, median (IQR)</b>	1.8 (0.97, 3.0)	2.0 (1.1, 3.3)	1.8 (0.9, 3.2)	0.23
<b>Primary renal disease, % / N</b>				0.30
<b>Diabetes mellitus type I &amp; II</b>	15.6 / 32	13.2 / 44	12.0 / 65	
<b>Hypertension/renovascular disease</b>	26.3 / 54	26.7 / 89	28.2 / 153	
<b>Glomerulonephritis/sclerosis</b>	19.0 / 39	17.1 / 57	12.9 / 70	
<b>Other</b>	36.6 / 75	41.4 / 138	45.0 / 244	
<b>Missing</b>	2.4 / 5	1.5 / 5	1.9 / 10	
<b>Initial RRT modality, % / N</b>				<0.001
<b>Haemodialysis</b>	71.2 / 146	76.6 / 255	71.4 / 387	
<b>Peritoneal dialysis</b>	15.6 / 32	10.8 / 36	15.7 / 85	
<b>Kidney transplant</b>	4.9 / 10	5.1 / 17	9.6 / 52	
<b>Missing</b>	8.3 / 17	7.5 / 25	3.3 / 18	
<b>Donor type, % / N</b>				0.03
<b>Living donor</b>	5.4 / 11	5.1 / 17	4.8 / 26	
<b>Deceased donor</b>	86.8 / 178	92.5 / 308	91.5 / 496	
<b>Unknown donor</b>	7.8 / 16	2.4 / 8	3.7 / 20	
<b>Donor age, median (IQR)</b>				
<b>Living donor</b>	67.5 (55.0, 74.0)	59.0 (25.0, 66.0)	60.0 (47.0, 71.0)	0.24
<b>Deceased donor</b>	71.0 (61.0, 76.0)	74.0 (68.0, 78.0)	75.0 (70.0, 79.0)	<0.001
<b>% missing (N)</b>	19.7 (34)	10.5 (35)	7.9 (43)	

RRT: Renal replacement therapy.



Table 4. Death- and graft failure rates per 1000-patient years with the 95% confidence interval (95%CI) for patients aged  $\geq 75$  to 84 years who received their first kidney transplant during 2005-2013, by transplant cohort.

	<b>2005-2007</b>	<b>2008-2010</b>	<b>2011-2013</b>
<b>Number of recipients</b>	205	333	542
<b>Patient death</b>			
<b>Number of death events</b>	111	118	94
<b>Total person-time at risk (yrs)</b>	939.9	1400.9	1182.7
<b>Death rate per 1000-patient yrs (95%CI)</b>	118.1 (96.1; 140.1)	84.2 (69.0; 99.4)	79.5 (63.4; 95.5)
<b>Graft failure</b>			
<b>Number of graft failure events</b>	120	145	146
<b>Total person-time at risk (yrs)</b>	856.0	1258.2	1077.2
<b>Graft failure rate per 1000-patient yrs (95%CI)</b>	140.2 (115.1; 165.3)	115.2 (96.5; 134.0)	135.5 (113.6; 157.5)

## Figures and legends

**Figure 1** Percentage of kidney transplants performed in patients aged  $\geq 75$  to 84 (left panel) and  $\geq 20$  to 74 years (right panel) in 2005-2014, by donor type; deceased donor (DD), living donor (LD) and unknown donor type (UD). Absence of a bar indicates that no transplants were performed in this age group. \*Data from Slovenia is for 2005-2013; data for Galicia is for 2007-14; and data for Madrid is for 2008-2014. BE: Belgium; ES: Spain.

**Figure 2** The age of deceased donors who donated a kidney, during 2005 to 2014 to prevalent patients on renal replacement therapy for end-stage renal disease, aged  $\geq 75$  to 84 years, presented by year of transplant. Donor age presented by median (black circle), mean (yellow diamond) and quartiles. Based on data from Austria, Denmark, Finland, France, Greece, Iceland, the Netherlands, Norway, the Spanish regions of Andalusia, Aragon, Asturias, Basque, Catalonia, Cantabria, Castile-La Mancha, Castile and Leon, Extremadura, Galicia (from 2007), Madrid (from 2008) and Scotland.

**Figure 3** Probability of patient survival (a), graft survival (b), and death-censored graft survival (c) in patients aged  $\geq 75$  to 84 years who received their first kidney transplant in 2005-2013 and by transplant cohort.

**Figure 4** Effect of transplant year on the hazard of patient death (a), graft failure (b) and death-censored graft failure (c), with 95% confidence bands for patients aged  $\geq 75$  to 84 years receiving their first kidney transplant between 2005 and 2013, and adjusted for country of transplantation, age at transplantation, sex, primary renal disease, dialysis vintage, and donor age and type (living versus deceased donor). The year 2009 was taken as the reference year.

**Supplementary figure 1** Cumulative risk of graft failure from all causes (i.e. graft failure and death) for patients aged  $\geq 75$  to 84 years who received their first kidney transplant between either 2005-2007 (cohort 1, 10-year follow-up), 2008-2010 (cohort 2, 7-year follow-up) and 2011-2013 (cohort 3, 4-year follow-up). \*Note the varying follow-up times/x-axis per cohort.



Supplementary Table 1. Number of prevalent patients aged  $\geq 75$  to 84 years on dialysis for end-stage renal disease, who received a kidney transplant, by country/region and overall, and by year during 2005-2014.

Year	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
<b>Austria</b>	4	5	4	4	$\leq 3$	8	5	9	$\leq 3$	6
<b>Belgium: Dutch-speaking</b>	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	4	$\leq 3$	$\leq 3$	$\leq 3$
<b>Belgium: French-speaking</b>	0	0	0	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	4	$\leq 3$
<b>Denmark</b>	0	0	0	0	0	0	$\leq 3$	0	0	0
<b>Finland</b>	0	$\leq 3$	0	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	4
<b>France*</b>	14	19	21	23	41	47	46	72	86	115
<b>Greece</b>	0	0	$\leq 3$	0	$\leq 3$	0	$\leq 3$	0	$\leq 3$	0
<b>Iceland</b>	0	0	0	0	0	$\leq 3$	0	0	0	0
<b>Netherlands</b>	9	$\leq 3$	7	4	13	13	14	21	21	20
<b>Norway</b>	8	10	6	9	10	7	17	14	10	13
<b>Slovenia</b>			0	0	0	0	0	0	0	
<b>Spain: Andalusia</b>	6	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	5	6	5	6
<b>Spain: Aragon</b>	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	4	4	5	5	6	6
<b>Spain: Asturias</b>	$\leq 3$	6	$\leq 3$	$\leq 3$	5	$\leq 3$	0	$\leq 3$	$\leq 3$	4
<b>Spain: Basque</b>	0	0	$\leq 3$	$\leq 3$	5	$\leq 3$	$\leq 3$	4	$\leq 3$	$\leq 3$
<b>Spain: Catalonia</b>	6	6	4	8	11	12	21	21	25	38
<b>Spain: Cantabria</b>	0	0	0	0	0	0	0	0	0	0
<b>Spain: Castile-La Mancha</b>	$\leq 3$	6	6	4	$\leq 3$	$\leq 3$	8	5	7	$\leq 3$
<b>Spain: Castile and Leon</b>	$\leq 3$	$\leq 3$	$\leq 3$	0	$\leq 3$	4	6	5	11	11
<b>Spain: Extremadura</b>	0	0	0	$\leq 3$	$\leq 3$	$\leq 3$	0	0	0	$\leq 3$
<b>Spain: Galicia</b>			$\leq 3$	$\leq 3$	0	0	$\leq 3$	$\leq 3$	0	0
<b>Spain: Madrid</b>				23	22	24	16	17	21	31
<b>Spain: Valencia</b>	0	0	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	0	4	$\leq 3$	$\leq 3$
<b>Sweden</b>	0	0	$\leq 3$	$\leq 3$	0	$\leq 3$	0	9	$\leq 3$	8
<b>UK: Scotland</b>	$\leq 3$	0	$\leq 3$	$\leq 3$	$\leq 3$	$\leq 3$	4	$\leq 3$	$\leq 3$	$\leq 3$
<b>All</b>	55	64	66	91	132	141	164	202	214	277

\*The coverage of the French Renal Registry (REIN) was 57.8% in 2005 and rose to 100% by 2012. Empty cells indicate that data are unavailable.

Supplementary Table 2. Number of prevalent patients aged ≥75 to 84 years on dialysis for end-stage renal disease, by country/region and overall, and by year during 2005- 2014.

<b>Country</b> \ <b>Year</b>	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>
<b>Austria</b>	834	853	851	877	930	964	994	997	1006	1022
<b>Belgium: Dutch-speaking</b>	1209	1340	1393	1460	1505	1574	1641	1667	1659	1668
<b>Belgium: French-speaking</b>	792	829	859	901	912	925	944	977	1015	1029
<b>Denmark</b>	469	483	516	535	538	542	556	566	561	584
<b>Finland</b>	362	356	366	362	352	369	370	388	383	393
<b>France*</b>	6046	7100	8021	8851	9884	11130	11479	11753	12155	12461
<b>Greece</b>	2005	2104	2227	2397	2542	2657	2771	2819	2944	2958
<b>Iceland</b>	13	17	19	19	18	20	20	24	23	24
<b>Netherlands</b>	1196	1368	1414	1568	1731	1805	1860	1880	1913	1954
<b>Norway</b>	296	299	318	325	347	338	341	345	337	346
<b>Slovenia</b>				290	318	327	334	357	365	
<b>Spain: Andalusia</b>	823	947	1050	1088	1155	1212	1209	1244	1256	1240
<b>Spain: Aragon</b>	179	175	187	200	195	215	203	213	225	220
<b>Spain: Asturias</b>	136	151	155	157	149	153	171	178	183	165
<b>Spain: Basque</b>	236	242	245	245	271	263	287	291	313	305
<b>Spain: Catalonia</b>	1156	1179	1193	1234	1288	1352	1378	1395	1457	1429
<b>Spain: Cantabria</b>	63	66	65	72	69	79	73	73	78	67
<b>Spain: Castile-La Mancha</b>	264	283	284	306	308	309	304	301	319	279
<b>Spain: Castile and Leon</b>	367	392	434	444	458	453	473	469	429	431
<b>Spain: Extremadura</b>	124	135	149	140	160	170	186	186	190	193
<b>Spain: Galicia</b>			412	459	485	521	537	521	519	536
<b>Spain: Madrid</b>				750	789	811	835	809	811	838
<b>Spain: Valencia</b>	822	862	902	939	1009	1005	1022	1075	1089	1090
<b>Sweden</b>	863	955	956	968	952	977	1005	975	991	1000
<b>UK: Scotland</b>	380	387	391	417	423	455	445	434	447	432
<b>All</b>	18635	20523	22407	25004	26788	28626	29438	29937	30668	30664

\*The coverage of the French Renal Registry (REIN) was 57.8% in 2005 and rose to 100% by 2012.  
Empty cells indicate that data are unavailable.

Supplementary Table 3. Percentage of prevalent patients aged  $\geq 75$  to 84 years on dialysis for end-stage renal disease expressed as a percentage of all adult dialysis patients aged  $\geq 20$  to 84 years, and the annual percentage change (APC) with 95% confidence interval (95%CI) by country/region and overall, and by year between 2005 and 2014. \* Signifies a p-value of  $<0.05$ .

Country	Year										APC (95% CI)
	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	
Austria	21.8	21.7	22.3	22.4	23.0	23.6	24.5	24.3	24.0	24.9	1.6 (1.2; 2.0)*
Belgium, Dutch-speaking	34.1	36.6	38.9	39.7	39.3	40.3	41.6	42.2	41.6	41.8	2.4 (1.3; 3.6)*
Belgium, French-speaking	32.5	32.9	33.5	34.2	33.5	33.1	33.6	33.7	34.3	34.4	0.5 (0.8; 3.3)*
Denmark	19.3	19.6	19.9	20.8	21.1	21.9	22.8	23.3	23.4	23.7	2.4 (1.7; 3.1)*
Finland	23.5	23.4	23.5	22.0	21.1	21.6	21.3	22.6	21.8	22.8	-0.7 (-2.0; 0.6)
France	28.3	29.7	31.0	30.9	32.1	32.9	32.6	32.1	32.1	31.8	1.1 (0.5; 1.8)*
Greece	23.9	24.5	25.3	26.9	27.7	28.4	29.3	29.7	30.6	30.3	2.8 (2.1; 3.5)*
Iceland	22.8	32.7	31.7	32.2	30.5	29.0	26.7	35.3	34.3	35.3	2.3 (-0.6; 5.3)
the Netherlands	21.0	22.9	25.0	26.8	28.4	29.6	30.6	31.0	31.4	32.3	4.8 (4.4; 5.2)*
Norway	32.2	31.3	31.5	30.3	30.7	30.1	30.1	30.0	29.0	28.5	-1.2 (-1.5; -0.9)*
Slovenia				20.6	22.5	23.5	24.5	26.3	27.2		
Spain, Asturias	31.7	35.3	36.9	36.3	34.1	34.1	36.1	36.8	35.6	31.6	0.0 (-1.5; 1.5)
Spain, Basque country	26.5	27.0	28.0	28.4	29.8	29.4	30.8	30.9	33.7	33.0	2.6 (2.1; 3.1)*
Spain, Catalonia	29.8	29.7	31.7	31.5	32.1	33.3	34.3	34.4	35.0	34.4	1.9 (1.4; 2.4)*
Spain, Cantabria	28.8	30.4	31.4	32.0	29.9	33.9	32.2	32.0	35.9	32.1	1.5 (0.2; 2.7)*
Spain, Castile-La Mancha	28.8	30.1	30.9	34.1	35.0	33.3	32.3	33.1	36.1	31.2	1.3 (-0.3; 2.9)
Spain, Castile and León	32.7	33.8	37.0	37.1	37.9	38.5	40.2	40.3	37.8	38.9	1.6 (0.0; 3.2)
Spain, Extremadura	24.2	26.0	28.8	26.2	29.0	28.4	31.4	30.1	30.5	30.9	2.4 (1.3; 3.6)*
Spain, Galicia			28.4	29.6	30.5	32.1	32.9	31.8	31.0	31.3	
Spain, Community of Madrid				29.7	30.6	31.1	32.0	31.6	31.0	30.9	
Spain, Valencian region	27.9	28.3	29.2	30.0	31.7	30.8	30.8	31.5	31.5	31.1	1.4 (0.9; 1.9)*
Sweden	25.7	27.2	27.7	28.4	27.5	27.3	27.6	27.2	27.5	27.4	0.6 (-0.3; 1.5)
United Kingdom, Scotland	19.0	18.6	18.6	20.1	20.4	21.8	21.7	21.1	22.4	21.8	2.1 (1.3; 2.9)*
All	26.3	27.4	28.7	29.2	30.0	30.7	31.1	31.1	31.2	31.1	1.8 (1.4; 2.2)*

Supplementary Table 4. The median age and interquartile range (IQR) of deceased donors for recipients of kidney transplants aged  $\geq 75$  to 84 years performed between 2005 and 2014, by country/region. When there were less than 5 transplants performed in a country/region, the median deceased kidney donor age is not shown.

<b>Country</b>	<b>Median (IQR)</b>
<b>Austria</b>	70.0 (64.0, 74.0)
<b>Finland</b>	63.5 (56.0, 67.0)
<b>France</b>	77.0 (72.0, 80.0)
<b>Netherlands</b>	65.0 (56.0, 70.0)
<b>Norway</b>	69.0 (61.0, 76.0)
<b>Spain: Andalusia</b>	69.5 (65.0, 73.0)
<b>Spain: Aragon</b>	75.1 (72.0, 78.0)
<b>Spain: Asturias</b>	71.0 (69.0, 74.0)
<b>Spain: Basque</b>	72.0 (68.0, 76.0)
<b>Spain: Catalonia</b>	76.0 (72.0, 80.0)
<b>Spain: Castile-La Mancha</b>	77.0 (75.0, 81.0)
<b>Spain: Castile and Leon</b>	74.0 (69.0, 78.5)
<b>Spain: Extremadura</b>	63.0 (63.0, 70.0)
<b>Spain: Galicia</b>	70.0 (69.0, 71.0)
<b>Spain: Madrid</b>	77.0 (73.0, 80.0)
<b>UK: Scotland</b>	61.0 (48.0, 67.0)